Lee Tien-Li 4
4 · Aardvark Therapeutics, Inc. · Filed Feb 19, 2025
Insider Transaction Report
Form 4
Lee Tien-Li
DirectorChief Executive Officer10% Owner
Transactions
- Conversion
Common Stock
2025-02-14+41,303→ 1,479,633 total - Purchase
Common Stock
2025-02-14$16.00/sh+16,542$264,672→ 1,496,175 total - Conversion
Series A Convertible Preferred Stock
2025-02-14−350,002→ 0 total→ Common Stock (41,303 underlying)
Holdings
- 1,474,028(indirect: By Spouse)
Common Stock
Footnotes (1)
- [F1]The Series A Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series A Convertible Preferred Stock had no expiration date.